237 related articles for article (PubMed ID: 38760825)
1. Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
Song Z; Miao X; Xie X; Tang G; Deng J; Hu M; Liu S; Leng S
Lipids Health Dis; 2024 May; 23(1):141. PubMed ID: 38760825
[TBL] [Abstract][Full Text] [Related]
2. Effect of CVAI on the incidence of MASLD compared to BMI in populations with different body types: A prospective cohort study in China.
Zhao Y; He Y; Zhang L; Liu J; Bai Y; Wang M; Zheng S
Nutr Metab Cardiovasc Dis; 2024 Feb; 34(2):307-316. PubMed ID: 37949714
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease.
Miwa T; Tajirika S; Imamura N; Adachi M; Horita R; Hanai T; Ng CH; Siddiqui MS; Fukao T; Shimizu M; Yamamoto M
JGH Open; 2024 Jun; 8(6):e13110. PubMed ID: 38895100
[TBL] [Abstract][Full Text] [Related]
4. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
Wakabayashi SI; Tamaki N; Kimura T; Umemura T; Kurosaki M; Izumi N
J Gastroenterol; 2024 Jun; 59(6):494-503. PubMed ID: 38570344
[TBL] [Abstract][Full Text] [Related]
5. Adherence to a healthy lifestyle including sleep and sedentary behaviors and risk of metabolic dysfunction-associated steatotic liver disease in Chinese adults.
Zhang S; Huo Z; Borné Y; Meng G; Zhang Q; Liu L; Wu H; Gu Y; Sun S; Wang X; Zhou M; Jia Q; Song K; Ma L; Qi L; Niu K
Prev Med; 2024 Jul; 184():107971. PubMed ID: 38657685
[TBL] [Abstract][Full Text] [Related]
6. Association between the ZJU index and risk of new-onset non-alcoholic fatty liver disease in non-obese participants: a Chinese longitudinal prospective cohort study.
Zheng K; Yin Y; Guo H; Ma L; Liu R; Zhao T; Wei Y; Zhao Z; Cheng W
Front Endocrinol (Lausanne); 2024; 15():1340644. PubMed ID: 38405152
[TBL] [Abstract][Full Text] [Related]
7. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
8. Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.
Martínez-Montoro JI; Martínez-Sánchez MA; Balaguer-Román A; Fernández-Ruiz VE; Hernández-Barceló JE; Ferrer-Gómez M; Frutos MD; Núñez-Sánchez MÁ; Fernández-García JC; Ramos-Molina B
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732557
[TBL] [Abstract][Full Text] [Related]
9. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
[TBL] [Abstract][Full Text] [Related]
10. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study.
Mayén AL; Sabra M; Aglago EK; Perlemuter G; Voican C; Ramos I; Debras C; Blanco J; Viallon V; Ferrari P; Olsen A; Tjønneland A; Langmann F; Dahm CC; Rothwell J; Laouali N; Marques C; Schulze MB; Katzke V; Kaaks R; Palli D; Macciotta A; Panico S; Tumino R; Agnoli C; Farràs M; Molina-Montes E; Amiano P; Chirlaque MD; Castilla J; Werner M; Bodén S; Heath AK; Tsilidis K; Aune D; Weiderpass E; Freisling H; Gunter MJ; Jenab M
BMC Med; 2024 Jun; 22(1):221. PubMed ID: 38825687
[TBL] [Abstract][Full Text] [Related]
11. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
12. Association between the composite dietary antioxidant index and metabolic dysfunction-associated steatotic liver disease in adults: a cross-sectional study from NHANES 2017-2020.
Yang Z; Song S; Li L; Yuan Z; Li Y
Sci Rep; 2024 Jun; 14(1):13801. PubMed ID: 38877074
[TBL] [Abstract][Full Text] [Related]
13. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
14. New insights into metabolic dysfunction-associated steatotic liver disease and oxidative balance score.
Peng L; Li L; Liu J; Li Y
Front Nutr; 2023; 10():1320238. PubMed ID: 38249604
[TBL] [Abstract][Full Text] [Related]
15. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
16. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
[TBL] [Abstract][Full Text] [Related]
17. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage.
Clayton-Chubb D; Kemp WW; Majeed A; Lubel JS; Woods RL; Tran C; Ryan J; Hodge A; Schneider HG; McNeil JJ; Roberts SK
Liver Int; 2024 Jan; 44(1):39-51. PubMed ID: 37698034
[TBL] [Abstract][Full Text] [Related]
18. Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver disease.
Cheng WC; Wong PY; Wu CD; Cheng PN; Lee PC; Li CY
Environ Health Prev Med; 2024; 29():7. PubMed ID: 38346730
[TBL] [Abstract][Full Text] [Related]
19. Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study.
Bao X; Kang L; Yin S; Engström G; Wang L; Xu W; Xu B; Zhang X; Zhang X
Alzheimers Res Ther; 2024 Jun; 16(1):136. PubMed ID: 38926784
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
